Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
about
Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acidsGemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trialsGemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.Recent treatment advances and novel therapies in pancreas cancer: a review.A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.S-1 in the treatment of pancreatic cancer.Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersSuccessful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of lifePlasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancerCombined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.The Role of Consolidation Chemo-Radiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma.
P2860
Q26739062-51177BA2-5535-40F5-A3D4-E7668875CCD6Q26786174-6E21D4C8-36AE-490E-9824-68F65AE7FAAAQ33412001-210A7C10-5689-4C76-832D-D9051EEBD1AEQ33416894-112D8230-B276-43F0-A9A7-56DFB39C140BQ33421322-3954DD70-C3F5-4C81-B3D4-4EFD6C69C694Q33427177-3F7F0AB4-0FBE-43E9-8547-B2757B00BF29Q33440500-DDE008B6-1384-4401-8351-2781A101E44DQ33441606-E59591CC-44C3-4642-B287-8248B5E4ABD5Q33442676-AF2289FF-25BC-466B-BEB0-43F61BA18425Q33625168-CB0BE13F-8B32-467E-B1F8-EA1C718C93F2Q34294011-2AB846E0-3AEF-433F-93FB-F6135A5C2E34Q34326711-B9637EFC-5A11-4A1F-8564-EFB52A8D93D7Q34467156-D7F65A73-C5A6-44BC-82BE-FE9A2CC997E6Q35545820-6343B05E-601D-4252-94DA-673D0064D331Q35604577-91A0A4A6-1A0A-40B8-8824-87426C4C103FQ36384541-3B26CC30-5D30-466A-BA71-E123E914FC6DQ36544488-7A958438-6EE2-44F6-909A-180F618AE6ADQ36750985-54323E43-D939-46C6-A64A-94289CB3342CQ37295836-C310B630-D303-4F22-BC38-1058CD4EF451Q38619215-AF2DE132-6C75-4A8A-A41D-39EDA1DB15F7Q38660283-8BBBC43F-B5AA-4182-99A5-60981236A5CCQ38673039-D7A8350A-3DC2-44AB-AFC7-654530715DC7Q39150005-15D4AD8C-E264-4F63-8773-B74A09514D73Q39364761-FC33EBD7-8EDE-42D3-A3EF-27D99873FEFBQ44038125-13555291-6B7B-4980-9892-E631E8817F73Q44618335-F7147F59-2037-444A-9625-239EC8D5919FQ44664897-5D53CBFD-9F5C-42C7-A933-74764B44B2B0Q46689245-77B8B157-633D-4FEB-9084-F4258DF7C6BCQ48323904-309971C3-9BB1-406C-B525-F7E0E8053A81Q53566415-18DB6D02-47A2-466C-9F6E-409019EB608F
P2860
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Randomized phase II study of g ...... rch Organization PC-01 study).
@ast
Randomized phase II study of g ...... rch Organization PC-01 study).
@en
type
label
Randomized phase II study of g ...... rch Organization PC-01 study).
@ast
Randomized phase II study of g ...... rch Organization PC-01 study).
@en
prefLabel
Randomized phase II study of g ...... rch Organization PC-01 study).
@ast
Randomized phase II study of g ...... rch Organization PC-01 study).
@en
P2093
P2860
P1476
Randomized phase II study of g ...... rch Organization PC-01 study).
@en
P2093
Atsushi Sofuni
Hiroshi Ishii
Hisatsugu Mouri
Iruru Maetani
Keiji Hanada
Masafumi Suyama
Masaji Tani
Masato Ozaka
Naoto Egawa
Ryouhei Watanabe
P2860
P2888
P304
P356
10.1007/S00280-012-1822-1
P577
2012-01-17T00:00:00Z
P5875
P6179
1037804249